US Pharma Sector M&A – 2Q & 3Q 2020 Dashboard: Trends, Transactions and Takeaways

Deal volumes and average ticket size significantly off from last year. Oncology remained the preferred area for buyers, with cannabis being an interesting second, albeit in much smaller deals. Expect slow and measured M&A activity within the US pharma sector, at least for a few more quarters.